Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Avidity Biosciences Inc (RNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RNA (3-star) is a STRONG-BUY. BUY since 20 days. Profits (36.46%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $66.89
1 Year Target Price $66.89
| 9 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 301.8% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.93B USD | Price to earnings Ratio - | 1Y Target Price 66.89 |
Price to earnings Ratio - | 1Y Target Price 66.89 | ||
Volume (30-day avg) 15 | Beta 0.95 | 52 Weeks Range 21.51 - 56.00 | Updated Date 08/15/2025 |
52 Weeks Range 21.51 - 56.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.9562 | Actual -1.21 |
Profitability
Profit Margin - | Operating Margin (TTM) -4448.71% |
Management Effectiveness
Return on Assets (TTM) -24.01% | Return on Equity (TTM) -37.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4749050235 | Price to Sales(TTM) 552.43 |
Enterprise Value 4749050235 | Price to Sales(TTM) 552.43 | ||
Enterprise Value to Revenue 442.64 | Enterprise Value to EBITDA -5.72 | Shares Outstanding 128653000 | Shares Floating 105526613 |
Shares Outstanding 128653000 | Shares Floating 105526613 | ||
Percent Insiders 4.81 | Percent Institutions 105.14 |
Upturn AI SWOT
Avidity Biosciences Inc
Company Overview
History and Background
Avidity Biosciences Inc. (RNA) was founded in 2012. It focuses on developing Antibody Oligonucleotide Conjugates (AOCs) as a new class of precision medicines. They aim to treat diseases with limited therapeutic options.
Core Business Areas
- AOC Platform Development: Avidity's core business revolves around its AOC platform, which combines the specificity of antibodies with the precision of oligonucleotide therapies.
- Therapeutic Development: Developing AOC therapeutics for muscle diseases, immunology, and other indications with unmet medical needs.
- Research and Development: Conducting preclinical and clinical research to advance their pipeline of AOC candidates.
Leadership and Structure
The leadership team includes Sarah Boyce (President and CEO). The company structure is typical of a biotechnology firm, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- AOC 1001 (DMD): AOC 1001 is their lead program targeting Duchenne Muscular Dystrophy (DMD). Phase 1/2 trial results are being evaluated. Market share is currently 0%, as it is pre-commercial. Competitors include Sarepta Therapeutics (SRPT) and Solid Biosciences (SLDB).
- AOC 1044 (DM1): AOC 1044 is being developed for the treatment of Myotonic Dystrophy Type 1 (DM1). Phase 1/2 trial results are being evaluated. Market share is currently 0%, as it is pre-commercial. Competitors include Ionis Pharmaceuticals (IONS) and Biogen (BIIB), though their approaches differ.
Market Dynamics
Industry Overview
The industry is characterized by high growth, innovation, and regulatory scrutiny. The gene therapy and RNA therapeutics markets are rapidly expanding.
Positioning
Avidity is positioned as a leader in the AOC field. Their competitive advantage lies in their proprietary AOC platform, which offers targeted delivery and enhanced efficacy. However, they are still clinical-stage and do not generate revenues yet.
Total Addressable Market (TAM)
The TAM for DMD and DM1 is estimated to be in the billions of dollars. Avidity is positioned to capture a significant portion of this market if their clinical trials are successful.
Upturn SWOT Analysis
Strengths
- Proprietary AOC platform
- Strong scientific team
- Promising preclinical and clinical data
- Targeting unmet medical needs
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on clinical trial success
- Relatively new technology platform
Opportunities
- Expansion of AOC platform to new disease targets
- Partnerships with larger pharmaceutical companies
- Regulatory approval of AOC candidates
- Advancements in oligonucleotide chemistry
Threats
- Clinical trial failures
- Competition from other gene therapy and RNA therapeutics companies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- SRPT
- IONS
- BIIB
- MRNA
Competitive Landscape
Avidity's competitive advantage lies in their AOC platform, which offers targeted delivery. However, they face competition from established gene therapy and RNA therapeutics companies with approved products.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by advancing clinical trials and expanding their pipeline.
Future Projections: Future growth is dependent on the success of their ongoing clinical trials and potential FDA approval of their AOC candidates. Analyst estimates vary widely but generally predict revenue generation within the next 2-3 years if trials are successful.
Recent Initiatives: Recent initiatives include advancing AOC 1001 and AOC 1044 into later-stage clinical trials, expanding the AOC platform to new disease targets, and securing partnerships.
Summary
Avidity Biosciences is a clinical-stage biotechnology company with a promising AOC platform. Their key strength is the targeted delivery of oligonucleotides via antibodies. Success hinges on the outcome of their clinical trials, specifically AOC 1001 and AOC 1044. Competition in the genetic medicine space is intense, and any clinical setbacks could negatively impact the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Company Website, Press Releases, Analyst Reports, Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on available information and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avidity Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-06-28 | President, CEO & Director Ms. Sarah Boyce | ||
Sector Healthcare | Industry Biotechnology | Full time employees 391 | |
Full time employees 391 | |||
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.